| Document Date: 2014-03-17 14:29:44
Open Document File Size: 1,12 MBShare Result on Facebook
Company Proteolix / Prism Pharmaceuticals / CyDex Pharmaceuticals / Ligand Pharmaceuticals / Baxter International / Onyx Pharmaceuticals Inc. / / Country United States / / Currency USD / / Event M&A / FDA Phase / Business Partnership / / Facility University of Kansas’ / / IndustryTerm pharmaceutical applications / plastics / well-proven technology / pharmaceuticals / pharmaceutical industry / manufacturing arrangement / pharma products / dependable and proven technology / reputable manufacturer / chemical attributes / formulation technology / aqueous systems / active pharmaceutical ingredients / inhalation products / physical and chemical properties / chemical structure / marketed products / / MedicalCondition multiple myeloma / respiratory failure / disease / CNS depression / acidosis / cardiac depression / severe hypotension / phlebitis / irritation / / Organization Higuchi Biosciences Center / University of Kansas / FDA / / Person Mike Auerbach / Matt Foehr / / Position Executive Vice President and Chief Operating Officer / Official / Editor in Chief / Official Media Sponsor / / Product Captisol / Nexterone / dV / Co-Solvent-Free Amiodarone Injection / Kyprolis™ / Kyprolis™ (Carfilzomib) / Kyprolis In / / ProvinceOrState Kansas / / Technology Captisol formulation technology / high-throughput screening / drug development / / URL www.PHARMPRO.COM / /
SocialTag |
Official Media Sponsor of INTERPHEX 2013™ New T e c hn o l o g y f o r th e b i o p h a r m /P h a r m a c e ut i c a l P r o f e s s i o n a l october 2012